Chronic Kidney Disease (CKD) poses a significant healthcare challenge in Saudi Arabia, necessitating a structured approach to management and treatment. Recent consensus guidelines in Saudi Arabia emphasize a comprehen...Chronic Kidney Disease (CKD) poses a significant healthcare challenge in Saudi Arabia, necessitating a structured approach to management and treatment. Recent consensus guidelines in Saudi Arabia emphasize a comprehensive strategy for CKD management, tailored to local needs and healthcare resources. The guidelines advocate for early detection and stratified care to mitigate the progression of CKD and improve patient outcomes. Key recommendations include the routine assessment of albuminuria and estimated glomerular filtration rate (eGFR) for accurate diagnosis and staging of CKD. The consensus underscores the importance of utilizing updated tools like the CKD-EPI 2021 equation for eGFR calculation and incorporating cystatin C measurements for enhanced diagnostic accuracy. Management strategies focus on controlling underlying conditions such as diabetes and hypertension, which are prevalent risk factors in the Saudi population. Personalized treatment plans are recommended, incorporating lifestyle modifications, pharmacological interventions including SGLT-2 inhibitors and GLP 1 RA, and regular monitoring to manage CKD complications effectively. The guidelines also highlight the need for specialized care and referral pathways for advanced CKD stages, including the role of nephrologists in the comprehensive management of CKD patients. In addition, the consensus addresses the need for improving public awareness and education about CKD, emphasizing early screening and preventive measures, particularly in high-risk groups. The implementation of these guidelines aims to optimize CKD management across Saudi Arabia, reduce the burden of kidney disease, and enhance overall patient care in the region.展开更多
According to recent epidemiological data, chronic kidney diseases (CKDs) affect approximately 10% of the global population. Like many countries, CKD is a significant public health issue in Saudi Arabia. The prevalence...According to recent epidemiological data, chronic kidney diseases (CKDs) affect approximately 10% of the global population. Like many countries, CKD is a significant public health issue in Saudi Arabia. The prevalence of CKD in Saudi Arabia is estimated to be around 4.5% of the adult population, with a higher prevalence in older age groups. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a class of oral medications used to treat type 2 diabetes mellitus (T2DM). In addition to their glucose-lowering effects, SGLT2i have been shown to have beneficial effects on kidney function in patients with or without T2DM. Therefore, a Saudi task force gathered to develop an explicit, evidence-based consensus on SGLT2i use in CKD Saudi patients. A panel of 14 experts made up a task force. An initial concept proposal was obtained. The proposal was divided into several topics discussed on 24 May 2023. A literature review was carried out. The literature search was completed on 3<sup>rd</sup> June 2023. A drafted report was distributed to the entire panel. Approval of the recommendations required consensus, defined as a majority approval (i.e. above 75%). The recommendations were revised to accommodate any differences of opinion until a consensus was reached. Recommendations were finally formulated on 21<sup>st</sup> June 2023. Subsequently, the panel reviewed and discussed the supporting rationale of the revised recommendations. This article presents these practical recommendations.展开更多
文摘Chronic Kidney Disease (CKD) poses a significant healthcare challenge in Saudi Arabia, necessitating a structured approach to management and treatment. Recent consensus guidelines in Saudi Arabia emphasize a comprehensive strategy for CKD management, tailored to local needs and healthcare resources. The guidelines advocate for early detection and stratified care to mitigate the progression of CKD and improve patient outcomes. Key recommendations include the routine assessment of albuminuria and estimated glomerular filtration rate (eGFR) for accurate diagnosis and staging of CKD. The consensus underscores the importance of utilizing updated tools like the CKD-EPI 2021 equation for eGFR calculation and incorporating cystatin C measurements for enhanced diagnostic accuracy. Management strategies focus on controlling underlying conditions such as diabetes and hypertension, which are prevalent risk factors in the Saudi population. Personalized treatment plans are recommended, incorporating lifestyle modifications, pharmacological interventions including SGLT-2 inhibitors and GLP 1 RA, and regular monitoring to manage CKD complications effectively. The guidelines also highlight the need for specialized care and referral pathways for advanced CKD stages, including the role of nephrologists in the comprehensive management of CKD patients. In addition, the consensus addresses the need for improving public awareness and education about CKD, emphasizing early screening and preventive measures, particularly in high-risk groups. The implementation of these guidelines aims to optimize CKD management across Saudi Arabia, reduce the burden of kidney disease, and enhance overall patient care in the region.
文摘According to recent epidemiological data, chronic kidney diseases (CKDs) affect approximately 10% of the global population. Like many countries, CKD is a significant public health issue in Saudi Arabia. The prevalence of CKD in Saudi Arabia is estimated to be around 4.5% of the adult population, with a higher prevalence in older age groups. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a class of oral medications used to treat type 2 diabetes mellitus (T2DM). In addition to their glucose-lowering effects, SGLT2i have been shown to have beneficial effects on kidney function in patients with or without T2DM. Therefore, a Saudi task force gathered to develop an explicit, evidence-based consensus on SGLT2i use in CKD Saudi patients. A panel of 14 experts made up a task force. An initial concept proposal was obtained. The proposal was divided into several topics discussed on 24 May 2023. A literature review was carried out. The literature search was completed on 3<sup>rd</sup> June 2023. A drafted report was distributed to the entire panel. Approval of the recommendations required consensus, defined as a majority approval (i.e. above 75%). The recommendations were revised to accommodate any differences of opinion until a consensus was reached. Recommendations were finally formulated on 21<sup>st</sup> June 2023. Subsequently, the panel reviewed and discussed the supporting rationale of the revised recommendations. This article presents these practical recommendations.
